Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.
Elizabeth Williams
CEO and co-founder, Hemideina
Contáctese con el equipo de la transacción
Transacciones relacionadas
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Aprenda másQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Aprenda másIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Aprenda más